Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8384568 | 0.86 | NCF1 (0.56) | MAPTKDM4ECYP3A4MEN1KMT2A | |
| SCHEMBL198641 | 0.78 | MAPT (0.64) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL217044 | 0.76 | MAPT (1.00) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL12992933 | 0.76 | MAPT (0.54) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL196873 | 0.74 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL610758 | 0.74 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL428159 | 0.74 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL3246068 | 0.74 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL609118 | 0.74 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL2907103 | 0.74 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021138298-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| CN-105130991-B | A kind of method for synthesizing bone morphogenetic protein acceptor inhibitor | 成都知普莱生物医药科技有限公司 | 2017-09-19 | — | — | CN | disclosed |
| EP-2529793-B1 | Compositions for regulating or modulating quorum sensing in bacteria, methods of using the compounds, and methods of regulating or modulating quorum sensing in bacteria | UNIV GEORGIA STATE RES FOUND (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-8653258-B2 | Compositions for regulating or modulating quorum sensing in bacteria, methods of using the compounds, and methods of regulating or modulating quorum sensing in bacteria | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8034944-B2 | Benzofluoranthene compound and organic light-emitting device using the compound | CANON KABUSHIKI KAISHA (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090278118-A1 | BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090278118-A1 | BENZOFLUORANTHENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | XDH, XPO6, PAX3 | MAPT 2798/4885KDM4E 1076/4885POLB 3906/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | MAPT 3902/4885KDM4E 484/4885POLB 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.